Glenmark launches Teneligliptin + Dapagliflozin Fixed Dose Combination, for Adults with Type 2 Diabetes, having Comorbidities

Glenmark Pharmaceuticals Limited (Glenmark), an innovation driven global pharmaceutical company, became the first to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed dose combination (FDC) for the treatment of adult patients with type 2 diabetes, especially the ones with comorbidities. Marketed under the brand name Zita D; it contains Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg), and must be taken once daily under prescription to improve glycemic control & prevent complications in adult patients with type 2 diabetes, especially the ones with comorbidities.

On the launch, Alok Malik, EVP & Business Head - India Formulations, Glenmark Pharmaceuticals, said, "Diabetes is growing in India at an alarming rate, and eight out of every ten diabetic patients suffer from comorbidities. Glenmark being a leader in the diabetes segment in India is proud to bring Zita D, a well researched and affordable fixed dose combination, which willsignificantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities."

Teneligliptin is a widely used DPP4i (Dipeptidyl Peptidase 4) inhibitor whereas Dapagliflozin isthe most prescribed SGLT 2i (Sodium glucose co transporter 2) inhibitorfor diabetic patientsin the country. While Zita D is a promising treatment option in managing uncontrolled Type 2 diabetes with co morbidities, this FDC has also proven to be effective among adult diabetic patients without comorbidities. Glenmark's Zita D is priced at around INR 14 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 5mg, and INR 15 per tablet for FDC of Teneligliptin 20 mg + Dapagliflozin 10 mg, per day.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 398.10 as compared to the previous close of Rs. 395.40. The total number of shares traded during the day was 23437 in over 887 trades.

The stock hit an intraday high of Rs. 403.00 and intraday low of 392.65. The net turnover during the day was Rs. 9324473.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 Teneligliptin Dapagliflozin FixedDoseCombination Type2Diabetes